Benefits
Digestive regularity
In a 4-week placebo-controlled crossover trial, 2,400 mg a day of Actazin increased average daily bowel movements in 19 healthy adults compared with the washout periods, with no change in stool form. In a smaller group of 9 adults with functional constipation, neither dose made a significant difference. A larger registered trial of Actazin in 240 adults was completed in 2020 but has not reported results.
Gut bacteria composition
A second analysis of the same trial measured stool bacteria. Actazin made few changes: the only significant shift was a small rise in Dorea bacteria in the constipated group at 2,400 mg a day, and stool organic acids did not change. The doubling of Faecalibacterium prausnitzii seen in that study followed a gold kiwifruit product, not Actazin.
Protein digestion
Actazin contains actinidin, an enzyme that breaks down protein. In a food-science study, beef injected with an Actazin solution broke down faster under simulated stomach conditions in a test tube. Rats fed green kiwifruit digested beef, gluten and soy protein faster in the stomach than rats fed gold kiwifruit, which lacks actinidin. No human study has tested Actazin for this.
Mechanism of action
Fiber and water retention
Kiwifruit contains soluble and insoluble fiber, which holds water in the gut. In the Actazin trial, healthy adults had more frequent bowel movements at 2,400 mg a day, but stool form did not change.
Actinidin proteolysis
The natural enzyme actinidin cuts dietary proteins into smaller pieces. In rats, actinidin from green kiwifruit increased protein digestion in the stomach for several protein sources.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial: Actazin 600 mg a day, Actazin 2,400 mg a day, a gold kiwifruit product (2,400 mg a day) and placebo, each for 28 days with 14-day washouts, with daily bowel-movement diaries. (Ansell et al. 2015, Nutrition Research)
19 healthy adults and 9 adults with functional constipation (Rome III criteria).
In healthy adults, Actazin 2,400 mg a day increased mean daily bowel movements compared with the washout periods; 600 mg a day reached significance only in a subgroup analysis of responders. Stool form did not change. In the constipated group, there were no significant differences between any of the treatments.
Randomized, double-blind, placebo-controlled crossover trial from the same study: each participant took Actazin 600 mg a day, Actazin 2,400 mg a day, a gold kiwifruit product and placebo for 4 weeks each, with 2-week washouts; stool bacteria were measured by gene sequencing. (Blatchford et al. 2017, Journal of Nutritional Science)
20 healthy adults (19 completed) and 9 adults with functional constipation.
Actazin made few changes to stool bacteria: the only significant shift was a rise in Dorea bacteria (0.9% to 1.4%) in the constipated group at 2,400 mg a day, and stool organic acids did not change. Faecalibacterium prausnitzii rose from 3.4% to 7.0% in the constipated group after the gold kiwifruit product, not after Actazin.